Advances in Neurotrophic Factor and Cell-Based Therapies for Parkinson's Disease: A Mini-Review

Gerontology
Michael D StaudtMatthew O Hebb

Abstract

Parkinson's disease (PD) affects an estimated 7-10 million people worldwide and remains without definitive or disease-modifying treatment. There have been many recent developments in cell-based therapy (CBT) to replace lost circuitry and provide chronic biological sources of therapeutic agents to the PD-affected brain. Early neural transplantation studies underscored the challenges of immune compatibility, graft integration and the need for renewable, autologous graft sources. Neurotrophic factors (NTFs) offer a potential class of cytoprotective pharmacotherapeutics that may complement dopamine (DA) replacement and CBT strategies in PD. Chronic NTF delivery may be an integral goal of CBT, with grafts consisting of autologous drug-producing (e.g., DA, NTF) cells that are capable of integration and function in the host brain. In this mini-review, we outline the past experience and recent advances in NTF technology and CBT as promising and integrated approaches for the treatment of PD.

Citations

Sep 9, 2017·Journal of Applied Physiology·Patrícia C R RabeloDanusa D Soares
Apr 10, 2017·Journal of Neural Transmission·Marc Morissette, Thérèse Di Paolo
Apr 18, 2020·Neurobiology of Disease·Simon M BenoitMatthew O Hebb
Nov 27, 2021·Molecular Biology Reports·Ava NasrolahiZahra Shabani

❮ Previous
Next ❯

Related Concepts

Related Feeds

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Related Papers

Minimally Invasive Therapy & Allied Technologies : MITAT : Official Journal of the Society for Minimally Invasive Therapy
Can YerebakanGustav Steinhoff
Rinshō shinkeigaku = Clinical neurology
Olivier Rascol
Annual Review of Neuroscience
D M Yurek, J R Sladek
© 2021 Meta ULC. All rights reserved